Search

Organon & Co

Cerrado

SectorSanidad

13.55 0.07

Resumen

Variación precio

24h

Actual

Mínimo

13.55

Máximo

13.56

Métricas clave

By Trading Economics

Ingresos

351M

146M

Ventas

-47M

1.5B

P/B

Media del Sector

14.538

64.641

BPA

0.71

Rentabilidad por dividendo

0.59

Margen de beneficios

10

Empleados

10,000

EBITDA

344M

409M

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

0.59%

2.31%

Fecha Próximo Dividendo

10 sept 2026

Próxima Fecha de Ex Dividendo

14 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

95M

3.6B

Apertura anterior

13.48

Cierre anterior

13.55

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

105 / 340 Clasificación en Healthcare

Organon & Co Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 ago 2026, 19:01 UTC

News
Correlated Moves

Ethereum is trading lower, reflecting a broader decline in correlated assets. It remains below its 20-day moving average amid routine market fluctuations.

1 ago 2026, 00:06 UTC

Social Media
News

TLT trades lower in after-market hours, reflecting a historically bearish period for bonds and targeting the $80 level amid rising interest rate expectations.

1 ago 2026, 00:06 UTC

News

Geopolitical tensions with Iran have boosted the United States Oil Fund LP, following President Trump's ordered military offensive in response to attacks on U.S. troops.

1 ago 2026, 00:06 UTC

News

Ameriprise Financial Inc shares are lower in after-market trading, despite strong second-quarter revenue of $4.90 billion and adjusted EPS of $11.07.

1 ago 2026, 00:02 UTC

News

UBS raised its price target on Hershey Co to $198, maintaining a Neutral rating. Shares are trading higher during after-market hours.

1 ago 2026, 00:02 UTC

News

Lattice Semiconductor shares are lower in after-market trading following a cautionary report citing declining sales and rising costs, with shares priced at $124.53.

1 ago 2026, 00:02 UTC

News

Snap Inc. shares rose to about $4.70 in after-market hours, supported by bullish options activity ahead of its August 3 earnings report.

1 ago 2026, 00:02 UTC

News
Social Media

NVIDIA Corp shares are lower in after-market hours amid broader market declines, despite recent strong performance relative to peers and a weekly gain.

1 ago 2026, 00:02 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blade design, boosting shares in after-market hours.

1 ago 2026, 00:02 UTC

News
Correlated Moves

JPMorgan Chase & Co shares are lower in after-market trading amid ongoing market rotation and rising bond yields affecting investor sentiment.

1 ago 2026, 00:02 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion. Shares declined in after-market trading despite strong earnings and net income growth.

1 ago 2026, 00:02 UTC

News

Exponent Inc shares are trading lower in after-market hours after UBS lowered its price target to $72 while maintaining a Neutral rating.

1 ago 2026, 00:02 UTC

News

Bloom Energy Corp is declining in after-market hours amid a class action lawsuit alleging securities fraud and broader market pressures.

1 ago 2026, 00:01 UTC

News

Quantum Corp shares are higher in after-market trading, supported by positive developments in the quantum computing industry and strong investor interest in the sector.

1 ago 2026, 00:01 UTC

News

UBS raised its price target on Bright Horizons to $88, as shares gain in after-market trading following three sessions of declines.

1 ago 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

1 ago 2026, 00:01 UTC

News

Newell Brands Inc shares are lower in after-market hours amid overall market declines. The company entered a five-year credit facility of up to $800 million.

1 ago 2026, 00:01 UTC

News

UBS raised its price target on Valero Energy Corp to $355, contributing to shares' gain during after-market hours on Friday.

1 ago 2026, 00:01 UTC

News

UBS maintains Buy rating on Saia Inc, lowering price target to $504. Shares are higher in after-market trading following the adjustment.

1 ago 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

1 ago 2026, 00:01 UTC

News

American Electric Power reported Q2 earnings of $1.36 per share and raised its 2026 guidance to $6.25 to $6.55, driving shares higher in after-market hours.

1 ago 2026, 00:01 UTC

News

Clean Energy Fuels Corp is trading lower in after-market hours following a cautionary analysis highlighting its subpar revenue growth and high production costs.

1 ago 2026, 00:01 UTC

News

Chevron Corp has reached an accord with Iraq to invest in two oil fields, enhancing production capabilities. Shares are trading higher in after-market hours.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 jul 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 jul 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 jul 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 jul 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

Comparación entre iguales

Cambio de precio

Organon & Co previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

105 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat